Neurogene Inc Market Cap ($550.23 Million)
Market Cap & Net Worth: Neurogene Inc (NGNE)
Neurogene Inc market cap. Neurogene Inc (NASDAQ:NGNE) has a market capitalization of $550.23 Million ($550.23 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11438 globally and #2961 in its home market, demonstrating a 2.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurogene Inc's stock price $27.58 by its total outstanding shares 19950314 (19.95 Million). Also see cash efficiency ratio of Neurogene Inc for how efficiently the company converts equity into cash flow.
Neurogene Inc Market Cap History (2015–2026)
Neurogene Inc market cap history from 2015 to 2026. Data shows change from $4.98 Billion to $550.23 Million (-19.68% CAGR). Check Neurogene Inc stock quote for real-time trading data and today's change.
Index Memberships
Neurogene Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #316 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1164 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.03% | #180 of 263 |
Weight: Neurogene Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurogene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurogene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore NGNE net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
493.04x
Neurogene Inc's market cap is 493.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $861.85 Million | $25.00 Million | -$31.59 Million | 34.47x | N/A |
| 2024 | $456.06 Million | $925.00K | -$75.14 Million | 493.04x | N/A |
Competitor Companies of NGNE by Market Capitalization
Companies near Neurogene Inc in the global market cap rankings as of November 5, 2026. Also see Neurogene Inc (NGNE) total assets for a full breakdown of the balance sheet.
Key companies related to Neurogene Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Neurogene Inc (2015–2026)
Market capitalization of Neurogene Inc from 2015 to today. Between 2015 and today, Neurogene Inc's market cap moved from $4.98 Billion to $ 550.23 Million, with a yearly change of -19.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $550.23 Million | +33.88% |
| 2025 | $410.98 Million | -9.89% |
| 2024 | $456.06 Million | +17.96% |
| 2023 | $386.64 Million | +90.37% |
| 2022 | $203.09 Million | -89.44% |
| 2021 | $1.92 Billion | -65.82% |
| 2020 | $5.63 Billion | +14.45% |
| 2019 | $4.92 Billion | +470.37% |
| 2018 | $861.85 Million | -81.63% |
| 2017 | $4.69 Billion | -28.77% |
| 2016 | $6.59 Billion | +32.29% |
| 2015 | $4.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Neurogene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $550.23 Million USD |
| MoneyControl | $550.23 Million USD |
| MarketWatch | $550.23 Million USD |
| marketcap.company | $550.23 Million USD |
| Reuters | $550.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more